Health Care & Life Sciences » Pharmaceuticals | Karessa Pharma Holding AB

Karessa Pharma Holding AB | Balance Sheet

Fiscal year is January-December. All values SEK Thousands.
2014
2015
2016
2017
Cash & Short Term Investments
34,259.00
63,144.00
52,171.00
39,497.00
Total Accounts Receivable
927.00
586.00
495.00
977.00
Other Current Assets
187.00
-
167.00
-
Total Current Assets
35,373.00
63,730.00
52,833.00
40,474.00
Net Property, Plant & Equipment
-
-
94.00
326.00
Total Investments and Advances
40,300.00
-
-
-
Intangible Assets
170,245.00
170,245.00
170,245.00
136,185.00
Total Assets
245,918.00
233,975.00
223,172.00
176,985.00
Accounts Payable
419.00
662.00
170.00
1,173.00
Other Current Liabilities
877.00
1,052.00
1,207.00
1,643.00
Total Current Liabilities
1,296.00
1,714.00
1,377.00
2,816.00
Total Liabilities
1,296.00
1,714.00
1,377.00
2,816.00
Common Equity (Total)
244,622.00
232,261.00
221,795.00
174,169.00
Total Shareholders' Equity
244,622.00
232,261.00
221,795.00
174,169.00
Total Equity
244,622.00
232,261.00
221,795.00
174,169.00
Liabilities & Shareholders' Equity
245,918.00
233,975.00
223,172.00
176,985.00

About Karessa Pharma Holding AB

View Profile
Address
Lahällsvägen 48
Täby AB 183 30
Sweden
Employees -
Website http://www.karessa.se
Updated 09/14/2018
Karessa Pharma Holding AB engages in the development and commercialization of products in the therapeutic area of erectile dysfunction. Its projects include K-01, K-02, and K-03. The company was founded by Fredrik Hubinette on September 11, 2013 and is headquartered in Täby, Sweden.